Corbus Pharmaceuticals Holdings Inc (CRBP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.86-19.89%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CRBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -52.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CRBP — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Sec…
Why it matters: The combination data may guide further trials in first-line OPSCC. The readout will test whether CRB-701 has a path beyond second-line use.
Watch forThe Q1 2027 readout shows tumor responses in first-line OPSCC patients and supports planning another trial.
Also watch forThe readout shows little or no tumor response, or Corbus delays the data beyond Q1 2027.
Why it matters: The Phase 1b result sets the case for taking CRB-913 into a larger study. A Phase 2 start would mark the next test of the obesity drug.
Supportive ifCorbus starts the CRB-913 Phase 2 monotherapy study by June 30, 2027.
Worry ifCorbus delays the study beyond June 2027, or says it will not proceed to Phase 2.
Why it matters: The reported 5% weight loss at 12 weeks is an early signal. More data can show whether the result came with tolerable side effects.
Watch forThe November 2026 update confirms about 5% mean weight loss at 12 weeks at 60 mg and reports no major safety concern.
Also watch forThe update lowers the 5% weight loss result or reports safety issues that limit more testing.
Why it matters: TEMPO-1 is Corbus’s registrational study for CRB-701 in second-line OPSCC. Enrollment progress tests whether the trial plan is moving ahead.
Supportive ifThe company reports that the first patient received a dose in September 2026. It gives a clear plan for continued TEMPO-1 enrollment.
Worry ifThe company reports that TEMPO-1 enrollment has not started, is paused, or has slipped beyond its stated plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$236 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $806 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,646 loss on $10,000 · 76.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.